TimesSquare Capital Management LLC Sells 5,275 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

TimesSquare Capital Management LLC decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 496,350 shares of the biopharmaceutical company’s stock after selling 5,275 shares during the period. TimesSquare Capital Management LLC owned 0.52% of Intra-Cellular Therapies worth $35,549,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Intra-Cellular Therapies by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 993,813 shares of the biopharmaceutical company’s stock valued at $71,177,000 after purchasing an additional 18,899 shares during the period. Lisanti Capital Growth LLC acquired a new position in Intra-Cellular Therapies during the 4th quarter worth approximately $3,788,000. M&T Bank Corp boosted its holdings in Intra-Cellular Therapies by 19.3% in the fourth quarter. M&T Bank Corp now owns 4,780 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 774 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Intra-Cellular Therapies by 14.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 17,574 shares of the biopharmaceutical company’s stock valued at $1,259,000 after acquiring an additional 2,210 shares during the period. Finally, Natixis Advisors L.P. grew its stake in Intra-Cellular Therapies by 8.2% in the fourth quarter. Natixis Advisors L.P. now owns 33,888 shares of the biopharmaceutical company’s stock valued at $2,427,000 after acquiring an additional 2,554 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Insider Buying and Selling at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 22,590 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the completion of the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $73,301,065.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Michael Halstead sold 7,907 shares of Intra-Cellular Therapies stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $69.53, for a total value of $549,773.71. Following the completion of the sale, the executive vice president now owns 29,700 shares of the company’s stock, valued at approximately $2,065,041. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Sharon Mates sold 22,590 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the sale, the chief executive officer now directly owns 1,050,309 shares in the company, valued at $73,301,065.11. The disclosure for this sale can be found here. Insiders have sold a total of 168,487 shares of company stock worth $11,364,950 over the last three months. 3.40% of the stock is currently owned by insiders.

Intra-Cellular Therapies Stock Down 5.9 %

ITCI stock traded down $4.21 during midday trading on Wednesday, hitting $67.00. The company’s stock had a trading volume of 994,208 shares, compared to its average volume of 934,258. The stock has a market cap of $6.49 billion, a price-to-earnings ratio of -45.89 and a beta of 1.01. The stock’s 50-day moving average price is $69.03 and its 200 day moving average price is $65.86. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm’s quarterly revenue was up 52.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.46) EPS. As a group, equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

ITCI has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Mizuho lifted their price objective on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the company a “buy” rating in a report on Monday, April 22nd. Canaccord Genuity Group boosted their target price on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $120.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 24th. Finally, The Goldman Sachs Group boosted their price objective on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a report on Wednesday, April 17th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.17.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.